

Clovis Oncology Inc (CLVS) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/C6EA2026093EN.html>

Date: September 2021

Pages: 58

Price: US\$ 125.00 (Single User License)

ID: C6EA2026093EN

Abstracts

Clovis Oncology Inc (CLVS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Clovis Oncology Inc (Clovis) is a biopharmaceutical company that develops and commercializes anti-cancer agents in the US and internationally. The company's lead product includes Rubraca, an oral small molecule inhibitor of poly ADP-ribose polymerase used for the treatment of adults with BRCA mutation associated metastatic castrate-resistant prostate cancer. Its major pipeline products include Rucaparib, which is intended for the treatment of ovarian cancer, prostate cancer, gastric cancer, and solid tumors with mutations in homologous recombination repair genes. The company's preclinical candidate, FAP-2286 is a peptide-targeted radionuclide therapy and imaging agent intended for the treatment of cancer. It operates in California, the US; Cambridge, the UK; and Milan, Italy; among others. Clovis is headquartered in Boulder, Colorado, the US.

Clovis Oncology Inc Key Recent Developments

Aug 04,2021: Clovis Oncology Announces Second Quarter 2021 Operating Results

Jul 12,2021: Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors

Jun 10,2021: Clovis Oncology Announces Partial Adjournment Of Annual Meeting Of Stockholders

May 05,2021: Clovis Oncology Announces First Quarter 2021 Operating Results

Apr 16,2021: Clovis Oncology to Announce First Quarter 2020 Financial Results and Host Webcast Conference Call on May 5

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Clovis Oncology Inc - Key Facts
Clovis Oncology Inc - Key Employees
Clovis Oncology Inc - Key Employee Biographies
Clovis Oncology Inc - Major Products and Services
Clovis Oncology Inc - History
Clovis Oncology Inc - Company Statement
Clovis Oncology Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Clovis Oncology Inc - Business Description
R&D Overview
Clovis Oncology Inc - Corporate Strategy
Clovis Oncology Inc - SWOT Analysis
SWOT Analysis - Overview
Clovis Oncology Inc - Strengths
Clovis Oncology Inc - Weaknesses
Clovis Oncology Inc - Opportunities
Clovis Oncology Inc - Threats
Clovis Oncology Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCENCES FINANCIAL DEALS AND ALLIANCES

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Clovis Oncology Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 04, 2021: Clovis Oncology Announces Second Quarter 2021 Operating Results
Jul 12, 2021: Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors
Jun 10, 2021: Clovis Oncology Announces Partial Adjournment Of Annual Meeting Of Stockholders
May 05, 2021: Clovis Oncology Announces First Quarter 2021 Operating Results
Apr 16, 2021: Clovis Oncology to Announce First Quarter 2020 Financial Results and Host Webcast Conference Call on May
Apr 16, 2021: Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February
Feb 23, 2021: Clovis Oncology announces 2020 operating results
Feb 17, 2021: Clovis Oncology to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Webcast Conference Call on February
Jan 11, 2021: Clovis Oncology announces preliminary product revenues for the fourth quarter and full year 2020
Nov 05, 2020: Clovis Oncology announces third quarter 2020 operating results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Clovis Oncology Inc, Key Facts
Clovis Oncology Inc, Key Employees
Clovis Oncology Inc, Key Employee Biographies
Clovis Oncology Inc, Major Products and Services
Clovis Oncology Inc, History
Clovis Oncology Inc, Other Locations
Clovis Oncology Inc, Subsidiaries
Clovis Oncology Inc, Key Competitors
Clovis Oncology Inc, Ratios based on current share price
Clovis Oncology Inc, Annual Ratios
Clovis Oncology Inc, Annual Ratios (Cont...1)
Clovis Oncology Inc, Annual Ratios (Cont...2)
Clovis Oncology Inc, Interim Ratios
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Clovis Oncology Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Clovis Oncology Inc, Performance Chart (2016 - 2020)

Clovis Oncology Inc, Ratio Charts

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Clovis Oncology Inc (CLVS) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/C6EA2026093EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C6EA2026093EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970